Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Beyond Low-Density Lipoprotein

Addressing the Atherogenic Lipid Triad in Type 2 Diabetes Mellitus and the Metabolic Syndrome

Abstract

The metabolic syndrome and type 2 diabetes mellitus are both becoming more prevalent, and both increase the risk of cardiovascular disease. Many patients are not receiving appropriate treatment for the type of dyslipidemia that commonly occurs in these disorders — the so-called ‘atherogenic lipid triad’ of high serum triglyceride levels, low serum high-density lipoprotein cholesterol (HDL-C) levels, and a preponderance of small, dense, low-density lipoprotein cholesterol (LDL-C) particles.

All of the processes involved in atherogenesis can be exacerbated by insulin resistance and/or the metabolic syndrome. Hypertriglyceridemia is a strong predictor of coronary heart disease. There is also an inverse relationship between serum levels of HDL-C and triglycerides in diabetic patients, with low serum HDL-C levels possibly representing an independent risk factor for cardiovascular disease. Small, dense, LDL-C particles are also highly atherogenic as they are more likely to form oxidized LDL and are less readily cleared. Insulin resistance, which is central to the metabolic syndrome and type 2 diabetes mellitus, leads to high levels of very low-density lipoprotein (VLDL), which contain a high concentration of triglycerides, resulting in high serum triglyceride levels and low serum HDL-C levels.

Even though modification of the atherogenic lipid triad is probably one of the most effective methods of reducing cardiovascular risk, therapy for diabetic dyslipidemia is often directed to first lowering serum LDL-C levels with a HMG-CoA reductase inhibitor. This may leave substantial excess risk for cardiovascular disease in patients with these types of dyslipidemia. The results of recent trials evaluating HMG-CoA reductase inhibitors have been mixed, with two showing no significant effect on cardiovascular outcomes in subgroups of diabetic patients. The recent CARDS (Collaborative Atorvastatin Diabetes Study) showed that atorvastatin can reduce cardiovascular events in a trial specifically designed for a diabetic population, though the population had to have at least one other risk factor in addition to diabetes mellitus.

Fibric acid derivatives, such as fenofibrate, bezafibrate and gemfibrozil, are potentially well suited to the treatment of dyslipidemia that is generally associated with type 2 diabetes mellitus and the metabolic syndrome, as they are usually more effective than HMG-CoA reductase inhibitors for normalizing serum levels of HDL-C and triglycerides. Promising results have been obtained from several trials of fibric acid derivatives including the BIP (Bezafibrate Infarction Prevention) study and the VA-HIT (Veterans Affairs Cooperative Studies Program HDL-C Intervention Trial; gemfibrozil). The FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial, a clinical outcomes trial specifically designed to evaluate fenofibrate in a large population of patients with type 2 diabetes mellitus, many of whom have the metabolic syndrome, is underway. The FIELD trial results should shed light on the efficacy and safety of fenofibrate in reducing cardiovascular morbidity in diabetic and metabolic syndrome patients and on the safety profile of combination therapy with fenofibrate and a HMG-CoA reductase inhibitor.

This is a preview of subscription content, log in to check access.

Table I
Table II
Table III

Notes

  1. 1.

    The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. 1.

    Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 Suppl. 2: S14–21.

  2. 2.

    Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–53.

  3. 3.

    Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34.

  4. 4.

    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.

  5. 5.

    Betteridge DJ. Treating dyslipidaemia in the patient with type 2 diabetes. Eur Heart J Suppl 2004; 6 Suppl. C: C28–33.

  6. 6.

    Drexel H, Aczel S, Marte T, et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 2005; 28: 101–7.

  7. 7.

    Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733–49.

  8. 8.

    Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Blood Press 1998; 7: 262–9.

  9. 9.

    NCEP Adult Treatment Panel III. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults final report. Circulation 2002; 106: 3143–421.

  10. 10.

    World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization, 1999.

  11. 11.

    The IDF consensus worldwide definition of the metabolic syndrome [online]. Available from URL: http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf [Accessed 2005 Jun 24].

  12. 12.

    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9.

  13. 13.

    Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004; 27: 2444–9.

  14. 14.

    Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 2001; 249: 225–35.

  15. 15.

    McKenney JM. Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: getting to goal. Pharmacotherapy 2003; 23: 26S–33S.

  16. 16.

    Eschwege E. The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications. Diabetes Metab 2003; 29: 6S19–27.

  17. 17.

    Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–16.

  18. 18.

    Cziraky MJ. Management of dyslipidemia in patients with metabolic syndrome. J Am Pharm Assoc (Wash) 2004; 44: 478–88.

  19. 19.

    Steiner G. Fibrates in the metabolic syndrome and in diabetes. Endocrinol Metab Clin North Am 2004; 33: 545–55, vi-vii.

  20. 20.

    Lehto S, Ronnemaa T, Haffner SM, et al. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997; 46: 1354–9.

  21. 21.

    Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823–8.

  22. 22.

    Papadakis JA, Milionis HJ, Press M, et al. Treating dyslipidaemia in non-insulindependent diabetes mellitus: a special reference to statins. J Diabetes Complications 2001; 15: 211–26.

  23. 23.

    Kendall DM. The dyslipidemia of diabetes mellitus: giving triglycerides and highdensity lipoprotein cholesterol a higher priority? Endocrinol Metab Clin North Am 2005; 34: 27–48.

  24. 24.

    Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453–62.

  25. 25.

    BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention study. Circulation 2000; 102: 21–7.

  26. 26.

    Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27 Suppl. 1: S68–71.

  27. 27.

    De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601–10.

  28. 28.

    Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498–511.

  29. 29.

    Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–16.

  30. 30.

    Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.

  31. 31.

    ALLHAT-LLT Trial Investigators. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 2002; 288: 2998–3007.

  32. 32.

    Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96.

  33. 33.

    Garg A. Statins for all patients with type 2 diabetes: not so soon. Lancet 2004; 364: 641–2.

  34. 34.

    Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165: 1154–60.

  35. 35.

    Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001; 3: 83–92.

  36. 36.

    Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410–8.

  37. 37.

    Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs Highdensity lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002; 162: 2597–604.

  38. 38.

    Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled study of bezafibrate: the St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 21: 641–8.

  39. 39.

    Diabetes Atherosclerosis Intervention Study. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905–10.

  40. 40.

    Keech A. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol 2005 Aug 22; 4(1): 13.

  41. 41.

    FIELD Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study [ISRCTN64783481]. Cardiovasc Diabetol 2004; 3: 9.

  42. 42.

    Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120–2.

  43. 43.

    Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002; 90: 50K–60K.

  44. 44.

    Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30: 1280–7.

  45. 45.

    Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin-treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001; 85: 544–8.

  46. 46.

    Reliant Pharmaceuticals Inc. Omacor® (omega-3-acid ethyl esters) prescribing information. Liberty Corner (NJ): Reliant Pharmaceuticals Inc., 2005 Apr.

  47. 47.

    Betteridge DJ, Morrell JM. Clinician’s guide to lipids and coronary heart disease. 2nd ed. London: Arnold, 2003.

  48. 48.

    The Lipid Research Clinics Coronary Primary Prevention Group. The lipid research clinics coronary primary prevention trial results: I. reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64.

  49. 49.

    Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once a night versus plain niacin in the management of hyperlipidemia. Metabolism 1998; 47: 1097–104.

  50. 50.

    Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1092–7.

  51. 51.

    Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24: 729–41.

  52. 52.

    Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 629 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409–15.

  53. 53.

    Betteridge DJ, Clark RAC, Choudhury RP. Lipid disorders: ezetimibe. Drugs in Context — General Medicine 2004; 1(2): 37–72.

Download references

Acknowledgments

The preparation of this manuscript was supported by Fournier. The author has received honoraria from Fournier. The author would like to thank Grace Townshend for editorial support in the preparation of this manuscript.

Author information

Correspondence to Prof. Richard W. Nesto.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nesto, R.W. Beyond Low-Density Lipoprotein. Am J Cardiovasc Drugs 5, 379–387 (2005). https://doi.org/10.2165/00129784-200505060-00005

Download citation

Keywords

  • Metabolic Syndrome
  • Fenofibrate
  • Ezetimibe
  • Gemfibrozil
  • Fibric Acid Derivative